Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage

Neurochemistry International

Volumn 62, Issue 1, 2013, Pages 1-7

  Cleeter, Michael W J ^a   Chau, Kai Yin ^a   Gluck, Caroline ^a   Mehta, Atul ^a   Hughes, Derralynn A ^a   Duchen, Michael ^a   Wood, Nicholas William ^a   Hardy, John ^a   Mark Cooper, J ^a   Schapira, Anthony Henry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha synuclein; Autophagy; Free radicals; Gaucher disease; Glucocerebrosidase; Membrane potential; Mitochondria; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

ADENOSINE DIPHOSPHATE; ALPHA SYNUCLEIN; CONDURITOL BETA EPOXIDE; EPOXIDE; FREE RADICAL; GLUCOSYLCERAMIDASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC RISK; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BLOTTING, WESTERN; CELL LINE; ELECTRON TRANSPORT; ENZYME INHIBITORS; FREE RADICALS; GLUCOSYLCERAMIDASE; HUMANS; INDICATORS AND REAGENTS; INOSITOL; LYSOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84870671394     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.10.010     Document Type: Article

References (27)

1. L. Alvarez-Erviti, M.C. Rodriguez-Oroz, J.M. Cooper, C. Caballero, I. Ferrer, J.A. Obeso, and A.H. Schapira Chaperone-mediated autophagy markers in Parkinson disease brains Arch. Neurol. 67 2010 1464 1472
2. J.L. Bradley, J.C. Blake, S. Chamberlain, P.K. Thomas, J.M. Cooper, and A.H. Schapira Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia Hum. Mol. Genet. 9 2000 275 282
3. G. Bultron, K. Kacena, D. Pearson, M. Boxer, R. Yang, S. Sathe, G. Pastores, and P.K. Mistry The risk of Parkinson's disease in type 1 Gaucher disease J. Inherit. Metab. Dis. 33 2010 167 173
4. M. Deganuto, M.G. Pittis, A. Pines, S. Dominissini, M.R. Kelley, R. Garcia, F. Quadrifoglio, B. Bembi, and G. Tell Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress J. Cell. Physiol. 212 2007 223 235
5. M.R. Duchen, A. Surin, and J. Jacobson Imaging mitochondrial function in intact cells Methods Enzymol. 361 2003 353 389
6. S. Gandhi, A. Wood-Kaczmar, Z. Yao, H. Plun-Favreau, E. Deas, K. Klupsch, J. Downward, D.S. Latchman, S.J. Tabrizi, N.W. Wood, M.R. Duchen, and A.Y. Abramov PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death Mol. Cell 33 2009 627 638
7. Gegg, M.E., Vurke, D., Heales, S.J.R., Cooper, J.M., Hardy, J., Wood, N.W., Schapira, A.H.V., in press. Glucocerebrosidase deficiency in substantia nigra of Parkinson's disease brains. Ann. Neurol.
8. G.A. Grabowski Phenotype, diagnosis, and treatment of Gaucher's disease Lancet 372 2008 1263 1271
9. L.V. Korlipara, J.M. Cooper, and A.H. Schapira Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells Neuropharmacology 46 2004 562 569
10. I. Kov-Bar, I. Ron, M. Filocamo, and M. Horowitz Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant Blood Cells Mol. Dis. 46 2011 4 10
11. A.B. Manning-Bog, B. Schule, and J.W. Langston Alpha-synuclein- glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism Neurotoxicology 30 2009 1127 1132
12. J.R. Mazzulli, Y.H. Xu, Y. Sun, A.L. Knight, P.J. McLean, G.A. Caldwell, E. Sidransky, G.A. Grabowski, and D. Krainc Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies Cell 146 2011 37 52
13. K.S. McNaught, and P. Jenner Proteasomal function is impaired in substantia nigra in Parkinson's disease Neurosci. Lett. 297 2001 191 194
14. J. Neumann, J. Bras, E. Deas, S.S. O'Sullivan, L. Parkkinen, R.H. Lachmann, A. Li, J. Holton, R. Guerreiro, R. Paudel, B. Segarane, A. Singleton, A. Lees, J. Hardy, H. Houlden, T. Revesz, and N.W. Wood Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease Brain 132 2009 1783 1794
15. D.S. Newburg, S. Yatziv, R.H. McCluer, and S. Raghavan Beta-Glucosidase inhibition in murine peritoneal macrophages by conduritol-β-epoxide: an in vitro model of the Gaucher cell Biochim. Biophys. Acta 877 1986 121 126
16. E.M. Prence, P. Chaturvedi, and D.S. Newburg In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology J. Neurosci. Res. 43 1996 365 371
17. S.S. Raghavan, J. Topol, and E.H. Kolodny Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease Am. J. Hum. Genet. 32 1980 158 173
18. S.P. Sardi, J. Clarke, C. Kinnecom, T.J. Tamsett, L. Li, L.M. Stanek, M.A. Passini, G.A. Grabowski, M.G. Schlossmacher, R.L. Sidman, S.H. Cheng, and L.S. Shihabuddin CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy Proc. Natl. Acad. Sci. USA 108 2011 12101 12106
19. A.H. Schapira Etiology of Parkinson's disease Neurology 66 2006 S10 S23
20. A.H. Schapira Mitochondrial diseases Lancet 379 2012 1825 1834
21. A.H. Schapira, and E. Tolosa Molecular and clinical prodrome of Parkinson disease: implications for treatment Nat. Rev. Neurol. 6 2010 309 317
22. A.H. Schapira, V.M. Mann, J.M. Cooper, D. Dexter, S.E. Daniel, P. Jenner, J.B. Clark, and C.D. Marsden Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease J. Neurochem. 55 1990 2142 2145
23. A.H. Schapira, M.W. Cleeter, J.R. Muddle, J.M. Workman, J.M. Cooper, and R.H. King Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons Ann. Neurol. 60 2006 253 255
24. E. Sidransky, M.A. Nalls, J.O. Aasly, J. Haron-Peretz, G. Annesi, E.R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, A. Brice, C.M. Chen, L.N. Clark, C. Condroyer, E.V. De Marco, A. Durr, M.J. Eblan, S. Fahn, M.J. Farrer, H.C. Fung, Z. Gan-Or, T. Gasser, R. Gershoni-Baruch, N. Giladi, A. Griffith, T. Gurevich, C. Januario, P. Kropp, A.E. Lang, G.J. Lee-Chen, S. Lesage, K. Marder, I.F. Mata, A. Mirelman, J. Mitsui, I. Mizuta, G. Nicoletti, C. Oliveira, R. Ottman, A. Orr-Urtreger, L.V. Pereira, A. Quattrone, E. Rogaeva, A. Rolfs, H. Rosenbaum, R. Rozenberg, A. Samii, T. Samaddar, C. Schulte, M. Sharma, A. Singleton, M. Spitz, E.K. Tan, N. Tayebi, T. Toda, A.R. Troiano, S. Tsuji, M. Wittstock, T.G. Wolfsberg, Y.R. Wu, C.P. Zabetian, Y. Zhao, and S.G. Ziegler Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease N. Engl. J. Med. 361 2009 1651 1661
25. X. Wang, B. Su, W. Liu, X. He, Y. Gao, R.J. Castellani, G. Perry, M.A. Smith, and X. Zhu DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease Aging Cell. 10 2011 807 823
26. K. Wong, E. Sidransky, A. Verma, T. Mixon, G.D. Sandberg, L.K. Wakefield, A. Morrison, A. Lwin, C. Colegial, J.M. Allman, and R. Schiffmann Neuropathology provides clues to the pathophysiology of Gaucher disease Mol. Genet. Metab 82 2004 192 207
27. T.L. Yap, J.M. Gruschus, A. Velayati, W. Westbroek, E. Goldin, N. Moaven, E. Sidransky, and J.C. Lee Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases J. Biol. Chem. 286 2011 28080 28088